PSU Watch logo

| Cancel bids for hydrocarbon extraction in Cauvery Basin, Stalin urges PM Modi |   | LIC looks to raise up to Rs 25,000 crore from anchor investors |   | NTPC invites EoI for Hydrogen Fuel Cell based pilot projects |   | Oil Minister defends high fuel prices citing govt spending on welfare schemes |  

DCGI approves anti-COVID drug developed by DRDO for emergency use

An anti-COVID drug that has been developed by the INMAS-DRDO in collaboration with Dr Reddy’s Laboratories, Hyderabad gets clearance for emergency use by the DCGI

DCGI approves anti-COVID drug developed by DRDO for emergency use
DCGI approves anti-COVID drug developed by DRDO for emergency use

New Delhi: An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. The higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.

DRDO lab developed 2-DG

DRDO took the initiative of developing the anti-COVID therapeutic application of 2-DG. In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of the Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against the SARS-CoV-2 virus and inhibits viral growth. Based on these results, the Drugs Controller General of India’s (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted a Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020.

The DRDO, along with its industry partner DRL, Hyderabad, started clinical trials to test the safety and efficacy of the drug in COVID-19 patients. In Phase-II trials (including dose-ranging) conducted from May to October 2020, the drug was found to be safe in COVID-19 patients and showed significant improvement in their recovery. Phase II-A was conducted in six hospitals and Phase II-B (dose-ranging) clinical trial was conducted at 11 hospitals all over the country. The overall phase-II trial was conducted on 110 patients.

Inefficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalisation of specific vital signs parameters when compared to SoC.

2-DG worked in trials, patients improved symptomatically

Based on successful results, DCGI further permitted the Phase-III clinical trials in November 2020. The Phase-III clinical trial was conducted on 220 patients between December 2020 to March 2021 at 27 COVID hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. The detailed data of the phase-III clinical trial was presented to DCGI. In the 2-DG arm, a significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by Day-3 in comparison to SoC, indicating an early relief from Oxygen therapy/dependence.

ALSO READ:

1. Oxygen crisis: DRDO to install five medical Oxygen plants in Delhi & Haryana

2. COVID-19: DRDO arranges big size oxygen cylinders for fulfilling requirements of different hospitals

A similar trend was observed in patients aged more than 65 years. On May 01, 2021, DCGI granted permission for the emergency use of this drug as an adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.

The drug comes in powder form in a sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.

In the ongoing second COVID-19 wave, a large number of patients are facing severe oxygen dependency and need hospitalisation. The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. This also reduces the hospital stay of COVID-19 patients.

(PSU Watch- India's Business News centre that places the spotlight on PSUs, Bureaucracy, Defence and Public Policy is now on Telegram & Twitter as well. Join PSU Watch Channel in your Telegram and follow us on Twitter to stay updated)